Pharmaceutical

Enveric’s EB-003 selected as lead candidate for mental health disorders

Enveric Biosciences has selected EB-003 as its lead drug candidate from its EVM301 series for difficult-to-treat mental health disorders.

Dec 30, 2023 - 18:00
Enveric’s EB-003 selected as lead candidate for mental health disorders
Enveric Biosciences has selected EB-003 as its lead drug candidate from its EVM301 series for difficult-to-treat mental health disorders.
Read the original article

Tags:

Previous Article

FDA warns of rare hypersensitivity reaction due to antiseizure drugs

Next Article

Greener and feasible production: Enzymatic methods for mono- and diacylglycerol ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Lumicell co-founder wins Nobel Prize in Chemistry

Lumicell co-founder wins Nobel Prize in Chemistry

Oct 5, 2023

UK NICE rejects Daiichi Sankyo’s Enhertu for breast cancer

UK NICE rejects Daiichi Sankyo’s Enhertu for breast cancer

Mar 7, 2024

STAT+: Pharmalittle: Eisai executive to retire; Express Scripts adds three Humira biosimilars to formulary

STAT+: Pharmalittle: Eisai executive to retire; Express...

Jul 12, 2023